Clinical Study Results Sanofi Pharma, including Sanofi Genzyme



Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter C

Generic Name Trade Name Condition Study Code Study Name Access to study Access to results
CABAZITAXEL Jevtana Prostatic Neoplasms EFC6193 TROPIC NCT00417079
CABAZITAXEL Jevtana Prostatic Neoplasms EFC11784 FIRSTANA NCT01308567
CABAZITAXEL Jevtana Neoplasms, Malignant TCD11068 NA NCT01001221
CABAZITAXEL Jevtana Cancer, Gastric ARD12417 GASTANA NCT01497964
CABAZITAXEL Jevtana Small Cell Lung Cancer ARD12166 NA NCT01500720
CABAZITAXEL Jevtana Prostatic Neoplasms CABAZ_L_05933 SWITCH NCT01576029
CABAZITAXEL Jevtana Prostatic Neoplasms CABAZ_L_06003 PROSPECTA NCT01649635
CABAZITAXEL Jevtana Neoplasms, malignant POP12251 NA NCT01527929
CABAZITAXEL Jevtana Neoplasms, malignant POP6792 NA NCT01140607
CABAZITAXEL Jevtana Prostate Cancer, Hormone Refractory TED11576 NA NCT01324583
CABAZITAXEL Jevtana Prostate Cancer TCD12128 NA NCT01511536
CABAZITAXEL Jevtana Prostatic Neoplasms CABAZ_C_05331 NA EudraCT:2010-021128-92
CABAZITAXEL Jevtana Prostate Cancer CABAZL06499 NA NCT02074137
CABAZITAXEL Jevtana Solid Tumors TED12689 NA NCT01751308
CABAZITAXEL Jevtana Prostate Cancer EFC11785 PROSELICA EudraCT: 2010-022163-35
CABAZITAXEL Jevtana Prostate Cancer CABAZL07239 PEGAZUS NCT02441894
CAPECITABINE/CYCLOPHOSPHAMIDE Not marketed Breast Cancer Metastatic CAPCYR07568 METRO-ABC NCT02664103
CELIVARONE Not marketed Arrhythmia Prophylaxis DRI10936 ALPHEE NCT00993382
CELIVARONE Not marketed Atrial Fibrillation DRI5165 MAIA NCT00233441
CELIVARONE Not marketed Arrhythmia DRI5349 ICARIOS NCT00232297
CELIVARONE Not marketed Atrial Fibrillation DRI5760 CORYFEE NCT00232310
CETYLPYRIDINIUM CHLORIDE Cepacol Canela Power Hygiene CPYRY_L_03930 NA NCT00687037
CETYLPYRIDINIUM CHLORIDE Cepacol Canela Power Hygiene CPYRY_L_04020 NA NCT00729599
CICLESONIDE Alvesco Asthma DFI6153 (AVE2635A/2001) NA NCT00174746
CICLESONIDE Alvesco Asthma EFC6161 (XRP1526B/3028) NA NA
CICLESONIDE Alvesco Asthma EFC6163 (XRP1526B/3030) NA NCT00174733
CICLESONIDE Alvesco Asthma EFC6164 (XRP1526B/3031) NA NCT00174720
CICLESONIDE Alvesco Asthma SFY6160 (XRP1526B/3027) NA NCT00254956
CLINDAMYCIN + BENZOYL PEROXIDE Benzaclin Topical/Duac Topical Acne Vulgaris DL6021-0505 NA NCT00377000
CLOFARABINE Clolar Leukemia BIOV-111 NA EudraCT: 2004-001853-27
CLOFARABINE Clolar Leukemia BIOV-121 NA NCT00924443
CLOFARABINE Clolar Leukemia CLO212* NA NCT00042341
CLOFARABINE Clolar Leukemia CLO222* NA NCT00042354
CLOFARABINE Clolar Leukemia CLO05908 NA EudraCT: 2015-001172-21
CLOFARABINE Clolar Leukemia CLO08808 NA EudraCT: 2015-001173-41
CLOFARABINE Clolar Leukemia CLO21800205 NA NCT00315705
CLOFARABINE Clolar Leukemia CLO24300606 CLASSIC II NCT00373529
CLOFARABINE Clolar Leukemia CLO34100405 CLASSIC I NCT00317642
CLOPIDOGREL Plavix Angina, Stable Myocardial Infarction C_9108 ALBION NCT00360386
CLOPIDOGREL Plavix Peripheral Vascular Diseases C_9253 CASPAR 2004 NCT00174759
CLOPIDOGREL Plavix Angina, Stable Myocardial Infarction EFC10675 CLEAN NCT00821834
CLOPIDOGREL Plavix Angina, Stable Myocardial Infarction EFC4505 CHARISMA NCT00050817
CLOPIDOGREL Plavix Cardiovascular Diseases EFC4912A ACTIVE A NCT00249873
CLOPIDOGREL Plavix Cardiovascular DIseases EFC4912I ACTIVE I NCT00249795
CLOPIDOGREL Plavix Angina, Stable Myocardial Infarction EFC5133 NA NCT00714961
CLOPIDOGREL Plavix Cardiovascular Diseases EFC5314 CLARINET NCT00396877
CLOPIDOGREL Plavix Acute Coronary Disease EFC5965 CURRENT/OASIS7 NCT00335452
CLOPIDOGREL Plavix Coronary Syndrome, Acute EFC6720 (DV7314-26) NA NCT00325390
CLOPIDOGREL Plavix Cardiovascular Diseases L_8564 NA NCT00648453
CLOPIDOGREL Plavix Thrombosis L_9317 CASTLE NCT00716924
CLOPIDOGREL Plavix Metabolic Syndrome L_9842 PROCLAIM NCT00296803
CLOPIDOGREL Plavix Heart Defect, Congenital LTS10916 CLARINET LT NCT00833703
CLOPIDOGREL Plavix Angina, Stable Myocardial Infarction PDY4422 PICOLO NCT00115375
CLOPIDOGREL Plavix Peripheral Arterial Disease SFY10810 NA NCT00862420
CLOPIDOGREL Plavix Cerebral infarction SFY6913 NA NCT00386191
CLOPIDOGREL Plavix Cerebrovascular accident CLOPI_L_02452 COMPRESS NCT00814268
CRF1 ANTAGONIST Not marketed Depression DFI5687 AGATE EudraCT: 2009-010339-42


References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted